Archive for August, 2009

Echelon Corp. (ELON) – Buzz Stock of the Day

Monday, August 10th, 2009


Shares of Echelon Corp. (NASDAQ: ELON) were up more than 45 percent today after the maker of energy efficiency products announced a long-term agreement to supply “smart meters” to Duke Energy Corp. (NYSE: DUK).

Duke Energy has described the smart grid as one of the greatest advancements of the 21st century,” said Ken Oshman, chairman and CEO of Echelon in a statement.

Echelon’s smart meters allow households to monitor electricity usage while also sending data back to power providers. By bringing the wide area network connection point down to the neighborhood transformer, the company’s NES architecture allows a utility to pinpoint problems in its network at a very precise location, and can improve customer service, for example, by eliminating cost and time associated with outage detection.

The creation of a “smart grid” is considered by some to be essential to modernizing the U.S. power delivery system, according to many experts.

“It’s the marriage of information technology and automation technology with the existing electricity network. This is the energy Internet,” said Bob Gilligan, vice president for transmission at GE Energy, which is aggressively pursuing smart grid development. “There are going to be applications 10 years from now that you and I have no idea that we’re going to want or need or think are essential to our lives.”

However, other experts warn that a “smart grid” isn’t smart enough yet to keep hackers away.

Mike Davis, a senior security consultant with Seattle-based IOActive Inc., demonstrated how a computer worm could hop between the meters at homes and businesses within a smart grid network. Such a worm could give troublemakers remote control of the meters, allowing them to disconnect someone’s power, for example.

“Every time we redesign a new technology like this, we’re doomed to relive the ’80s and ’90s all over again and the same vulnerabilities,” he told the AP.

Duke Energy has received regulatory approval to deploy smart grid infrastructure in Ohio, and plans to launch a five-year mass deployment of smart grid technology later this year including more than 700,000 electric smart meters in Ohio. In Indiana, Duke Energy is seeking approval from the Indiana Utility Regulatory Commission to install smart grid technology, including approximately 800,000 smart meters.

Echelon said the deal could represent a revenue opportunity of $150 million. The initial order is worth $15.8 million, with deliveries expected to begin at the end of the quarter, the company said.

Transcept Pharmaceuticals Inc. (TSPT) – Buzz Stock of the Day

Monday, August 3rd, 2009

Shares of Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT) jumped $3.75 or 64.7 percent to $9.55 in morning trading on Monday, after the company announced a licensing deal for its insomnia treatment with Purdue Pharmaceuticals for up to $145 million, and royalty payments.

“This agreement is a transforming event for Transcept,” said Glenn A. Oclassen, President and CEO of Transcept Pharmaceuticals in a statement.

[–quote–]

Under the terms of the agreement, Purdue was granted the exclusive rights to sell Intermezzo in the U.S. and is able to negotiate for its approval in Mexico and Canada. Transcept Pharmaceuticals retains the rights to the drug in all other countries and has the option to co-promote Intermezzo to psychiatrists in the U.S.

The agreement states that Purdue will pay Transcept $25 million upfront, and up to $30 million more based on approval timing by the FDA. Additionally, Transcept could receive as much as $90 million more based on future benchmarks related to intellectual property and sales milestones.

The deal also includes royalties of greater than 10 percent and as much as about 25 percent for the Richmond, Calif.-based Transcept. If Transcept exercises the psychiatric co-promotion option, it will receive an additional double-digit royalty on those sales. Transcept can begin co-promotion as soon as one year after launch.

“We are excited to be working with Transcept towards the launch of this potential new entry into the prescription sleep aid market,” said Purdue’s President and CEO John H. Stewart. “This agreement is part of Purdue’s plan to diversify our product portfolio and broaden our commercial focus into therapeutic areas that complement our leadership position in pain.”

The active ingredient in Intermezzo is zolpidem, the same active ingredient in other insomnia sleep aids, such as Ambien. However, Intermezzo only has about one-third-to-one-quarter zolpidem as other insomnia treatments.

“We believe that Intermezzo has the potential to occupy an important position in the substantial worldwide market for prescription sleep aids, and that our U.S. partnership with Purdue is a key step toward the commercial success of Intermezzo.”

Buzz Stock of the Day- Anadys Pharmaceuticals Inc. (ANDS)

Saturday, August 1st, 2009

Shares of Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) soared today after the San Diego-based company announced that U.S. Food and Drug Administration regulators approved the design of a study for its hepatitis C treatment.

Shares were up $1.32, or 73 percent from yesterday’s closing price in morning trading, and closed the day 45 percent higher at $2.60 per share.

The company’s hepatitis C treatment, ANA598, has “demonstrated potent antiviral activity and good tolerability as a single agent in Phase 1, as well as preclinical properties indicative of likely synergy when used clinically in combination regimens,” according to CEO, Steve Worland, Ph.D. “This trial incorporates several attractive features designed to further enhance the competitive position of ANA598, including twelve weeks of triple combination treatment and a randomized exploration of shortening the overall duration of HCV therapy in conjunction with ANA598 treatment.”

The FDA approval establishes the length and goals of the study, which clarifies what is considered successful testing. The study was previously sidelined when three participants dropped out of testing after developing a rash.

Anadys said the FDA cleared the study protocol and patient dosing is expected to start in the next several weeks. Ninety patients are planned to be enrolled in the study, with 30 patients receiving the drug, ANA598, and 15 receiving a dummy drug at each dose level. The study would test 200 mg and 400 mg doses of the drug.

For the second quarter, the company posted a net loss of $6.5 million, or 21 cents a share, compared with a net loss of $7.1 million, or 25 cents a share, a year ago. The company’s cash, cash equivalents and securities available for sale as of June 30 totaled $30.6 million compared to $27.9 million as of December 31, 2008. These cash reserves are expected to fund operations into 2011.

“With our enhanced cash position, reduced cost structure and Phase II protocol allowance from the FDA, we are well positioned to continue advancing the development of ANA598 as a treatment for chronic hepatitis C,” Worland said in a statement.